Karakteristik Ketebalan Makula Sentral Sebelum dan Sesudah Injeksi Intravitreal Bevacizumab di RSKM Padang Eye Center Periode Januari 2018 – Januari 2019

Haves Ashan

Abstract


Latar belakang: Edema makula merupakan penyebab umum terjadinya penurunan tajam penglihatan. Akumulasi cairan di dalam retina dan peningkatan ketebalan retina menyebabkan rusaknya blood retinal barrier. Injeksi intravitreal anti-VEGF (bevacizumab) bertujuan untuk mengurangi aktivitas VEGF, dimana oklusi vena pada retina (Retinal Vein Occlusion/ RVO) menginduksi peningkatan kadar VEGF yang menyebabkan peningkatan permeabilitas vaskular dan menimbulkan edema makula. Tujuan: Mengetahui ketebalan makula sentral sebelum dan sesudah injeksi intravitreal bevacizumab pada pasien oklusi vena retina sentral dan oklusi vena retina cabang melalui pengamatan hasil pemeriksaan OCT (Optical Coherence Tomography). Metode: Penelitian ini merupakan penelitian deskriptif retrospektif berdasarkan hasil penelusuran rekam medis terhadap 8 pasien RVO di RSKM Padang Eye Center periode Januari 2018 sampai Januari 2019. Penelitian dilakukan pada bulan Maret hingga April 2020. Hasil: Subyek penelitian sebanyak 8 orang (8 mata) terdiri dari 2 laki-laki (25,0%) dan 6 perempuan (75,0%). Rentang usia berkisar antara 41-80 tahun. Ketebalan makula sentral saat awal didapatkan mayoritas > 300 µm yaitu sebanyak 7 orang (87,5%), sedangkan ≤ 300 µm sebanyak 1 orang (12,5%). Satu bulan pasca injeksi didapatkan mayoritas ketebalan makula sentral ≤ 300 µm sebanyak 5 orang (62,5%), sedangkan    > 300 µm yaitu sebanyak 3 orang (37,5%). semua pasien mengalami penurunan ketebalan makula sentral yaitu sebanyak 8 subjek (100%). Kesimpulan: Semua pasien mengalami penurunan ketebalan makula sentral 1 bulan pasca injeksi intravitreal bevacizumab

Keywords


Edem Makula, OCT, Oklusi Vena Retina, RVO.

Full Text:

PDF

References


Doguizi, Sibel, et al. Case report: A rare Cause of Unilateral Central Retinal Vein occlusion in a Young Pasient: Type III Mixed Cryoglobulinemia. Ophthalmological Medicine; 2016. 2016. pp:1-4.

Pichi, Fransisco, et al. Central Retinal Vein Occlusion. American Academy of Ophtahlmology. United States. 2016.

Patel, Amy. Central retinal Vein Occlusion: A Review of Current Evidence-based Treatment Option. Midle East African Journal of Ophthalmology; 23(1). 2016. pp:44-48.

Noma, Hidetaka. Clinical Diagnosis in Central Retinal Vein Occlusion. J Med Diagn Meth; 2(2). 2013. pp:1-4.

Enany H. Evaluation of early versus late intravitreal bevacizumab injection in the treatment of macular edema secondary to branch retinal vein occlusion. Delta Journal of Ophthalmology; 19(1). 2018. pp:58-64.

Hikichi T, et al. Two-year outcomes of intravitreal bevacizumab therapy for macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmo; 98. 2014. pp:195-199.

Kartasasmita A, Takarai S, Switania A et al. Efficacy of single bevacizumab injection as adjuvant therapy to laser photocoagulation in macular edema secondary to branch retinal vein occlusion. Clinical Ophthalmology; 10. 2016. pp:2135–2140.

Campochiaro PA, Bhisitkul RB, Shapiro H, Rubio RG. Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology; 120(4). 2013. pp:795–802.

Yuan A, Ahmad B, Xu D et al. Comparison of intravitreal ranibizumab and bevacizumab for the treatment of macular edema secondary to retinal vein occlusion. Int J Ophthalmol; 7(1). 2014. pp:86-91.

Agarwal P, Saini VK, Gupta S et al. Evaluation of Central Macular Thickness and Retinal Nerve Fiber Layer Thickness using Spectral Domain Optical Coherence Tomography in a Tertiary Care Hospital. J Curr Glaucoma Pract; 8(2). 2014. pp:75-81.

Chan A, Duker J, Ko T. Normal Macular Thickness Measurements in Healthy Eyes Using Stratus Optical Coherence Tomography. Arch Ophthalmol; 124(2). 2006. pp:193-198.

Adhi M, Aziz S, Muhammad K et al. Macular Thickness by Age and Gender in Healthy Eyes Using Spectral Domain Optical Coherence Tomography. PLoS ONE; 7(5). 2012. pp:37-38.

Ehlers J, Kim S, Yeh S. Therapies for Macular Edema Associated with Branch Retinal Vein Occlusion. Ophthalmology ; 124. 2017. pp:1412-1423.

Mehany S, Mourad K, Shawkat A et al. Early Avastin management in acute retinal vein occlusion. Saudi Journal of Ophthalmology; 24. 2010. pp:87-94.

Kriechbaum K, Michels S, Prager F et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br. J. Ophthalmol; 92(4). 2008. pp:443.

Adjievska B, Boskurt S, Orovcanec N et al. The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions. Clinical Ophthalmology; 11. 2017. pp:1183–1190.




DOI: https://doi.org/10.33854/heme.v2i2.451

Refbacks

  • There are currently no refbacks.


Copyright (c) 2020 Health & Medical Journal

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Creative Commons License   Health and Medical Journal This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.